Mayo Alliance Prognostic System (MAPS) Score
The Mayo Alliance Prognostic System (MAPS) score provides a one‑sentence description as requested: A prognostic tool used to stratify survival risk in patients with systemic mastocytosis.
Indications for Use
Used for patients with systemic mastocytosis to predict overall survival and guide risk stratification at diagnosis. Incorporates age, cytopenias, alkaline phosphatase, disease subtype, and high‑risk mutations (ASXL1, RUNX1, NRAS) identified as independent prognostic factors in a 580‑patient cohort 1 [Level II evidence]. Validated to distinguish indolent/smoldering from advanced disease in real‑world cohorts 2 [Level III evidence], supporting prognostic counseling and therapeutic planning.
Insights & Cautions
Uses combined clinical (age, cytopenias, ALP, disease subtype) and molecular variables to stratify survival in systemic mastocytosis but is not calibrated for perioperative or surgical risk. Caution: derived from retrospective cohorts and may overestimate individual risk, especially when applied outside hematologic settings; external validation is limited and mostly academic. Should supplement—not replace—clinical judgment, as emphasized in validation work 1 [Level II evidence].